Wheelock J B, Krebs H B, Goplerud D R
Department of Obstetrics and Gynecology, Medical College of Virginia, Richmond 23298.
Gynecol Oncol. 1990 Apr;37(1):21-3. doi: 10.1016/0090-8258(90)90300-a.
Seventeen patients with recurrent cervical cancer were prospectively treated with a combination of bleomycin, vincristine, and mitomycin C (BOM). All patients had previously failed a cis-platinum-containing combination regimen. There were no complete responses. Four patients had partial responses, six patients had stable disease, and seven patients had no response. The median length of survival for responders was the same as that for nonresponders (5 months). More than 50% of patients experienced significant toxicity. The combination of bleomycin, vincristine, and mitomycin C appears to be ineffective as a second-line chemotherapy regimen against recurrent cervical cancer previously treated with cis-platinum.
17例复发性宫颈癌患者接受了博来霉素、长春新碱和丝裂霉素C（BOM）联合治疗。所有患者先前含顺铂的联合治疗方案均失败。无完全缓解病例。4例部分缓解，6例病情稳定，7例无反应。缓解者的中位生存期与未缓解者相同（5个月）。超过50%的患者出现明显毒性。博来霉素、长春新碱和丝裂霉素C联合方案作为二线化疗方案用于先前接受顺铂治疗的复发性宫颈癌似乎无效。
